|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The role of photovaporization of the prostate in small volume benign prostatic hyperplasia and review of the literature显示文摘Objective:Our objective was to characterize the safety and efficacy of the 180 W XPS-GreenLight laser in men with lower urinary tract symptoms secondary to a small volume benign prostatic hyperplasia(BPH).Methods:A retrospective analysis was performed for all patients who underwent 180 W XPSlaser photoselective vaporization of the prostate(PVP)vaporization of the prostate between 2012 and 2016 at two-tertiary medical centers.Data collection included baseline comorbidities,disease-specific quality of life scores,maximum urinary flow rate(Qmax),postvoid residual(PVR),complications,prostate volume and prostate-specific antigen(PSA).The secondary endpoints were the incidence of intraoperative and postoperative adverse events.Complications were stratified using the Clavien-Dindo grading system up to 90 days after surgery.Results:Mean age of men was 67.8 years old,with a mean body mass index of 29.7 kg/m2.Mean prostate volume as measured by transrectal ultrasound was 29 mL.Anticoagulation use was 47%and urinary retention with catheter at time of surgery was 17%.Mean hospital stay and catheter time were 0.5 days.Median follow-up time was 6 months with the longest duration of follow-up being 22.5 months(interquartile range,3-22.5 months).The International Prostate Symptom Score improved from 22.8±7.0 at baseline to 10.7±7.4(p<0.01)and 6.3±4.4(p<0.01)at 1 and 6 months,respectively.The Qmax improved from 7.70±4.46 mL/s at baseline to 17.25±9.30 mL/s(p<0.01)and 19.14±7.19 mL/s(p<0.001)at 1 and 6 months,respectively,while the PVR improved from 216.0±271.0 mL preoperatively to 32.8±45.3 mL(p<0.01)and 26.2±46.0 mL(p<0.01)at 1 and 6 months,respectively.The PSA dropped from 1.97±1.76 ng/mL preoperatively to 0.71±0.61 ng/mL(p<0.01)and 0.74±0.63 ng/mL at 1 and 6 months,respectively.No patient had a bladder neck contracture postoperatively and no capsular perforations were noted intraoperatively.Conclusion:The 180 W GreenLight XPS system is safe and effective for men with small volume BPH.PVP produced improvements in symptomatic and clinical parameters without any safety concern.It represents a safe surgical option in this under studied population. | Dominique Thomas Kevin C.Zorn Malek Meskawi Ramy Goueli Pierre-Alain Hueber Lesa Deonarine Vincent Misrai Alexis Te Bilal Chughtai | 2019 | Asian Journal of Urology2019，6，4： | 6 |
| 2 | HepG2 cells support viral replication and gene expression of hepatitis C virus genotype 4 in vitro显示文摘瞄准:与丙肝的长期的复制建立一个房间文化系统病毒(HCV ) 染色体和病毒的抗原的表示在试管内。方法:HepG2 房间线被孵化与长期的丙肝从一个病人与浆液为它的危险性测试到 HCV。房间和上层清液在文化期间在各种各样的时间点被收获。文化上层清液为它感染天真的房间的能力被测试。存在减(反感觉) 在房间的核心和 E1 抗原的 RNA 海滨,和察觉被 RT-PCR 和免疫学的技术(流动血细胞计数和西方的污点) 分别地检验。结果:细胞内部的 HCV RNA 首先在 d 上被检测 3 在感染以后然后能一致地在至少三个月的一个时期上在房间和上层清液被检测。新鲜房间能从有教养的感染的房间感染上层清液。流动 cytometric 分析证明表面和在房子里使用的细胞内部的 HCV 抗原表示使 polyclonal 成为了抗体(反核心,和 anti-E1 ) 。西方的污点分析证明在分子量的产生免疫性的肽的簇的表示在一个月内在 31 和 45 kDa 之间延长了感染的房间的旧文化而这簇在 uninfected HepG2 房间是无法发现的。结论:HepG2 房间线产生 HCV 感染而且支持它的复制在试管内不仅。HCV 结构的蛋白质的表示能在感染的 HepG2 房间被检测。这些房间也能够流病毒的粒子进接着对 uninfected 房间变得传染的培养基。 | Mostafa K El-Awady Ashraf A Tabll Yasmine S El-Abd Mahmoud M Bahgat Hussein A Shoeb Samar S Youssef Noha G Bader El Din El-Rashdy M Redwan Maha El-Demellawy Moataza H Omran Wael T El-Garf Said A Goueli | 2006 | World Journal of Gastroenterology2006，12，30： | 2 |
| 3 | Upregulation of the Catalytic Telomerase Subunit by the Transcription Factor ER81 and Oncogenic HER2/Neu,Ras,or Raf显示文摘 | Goueli B S Janknecht R | 2004 | Mol Cell Biol2004，24，1： | 1 |
| 4 | Upregulation of the catalytic telomerase subunit by the transcription factor ER81 and oncogenic HER2/Neu, Ras, or Rat显示文摘 | Goueli B S Janknecht R | 2004 | Mol Cell Biol2004，24，1： | 1 |
| 5 | T - cell acute lym- phoblastic leukemia - the associated gene SCL/tal codes for a 42 - Kd nuclear phosphoprotein 显示文摘 | Goldfarb AN Goueli S Mickelson D | 1992 | Blood1992，80，11： | 1 |
| 6 | Up-regulation of the catalytic telomerase subunit by the transcription factor ER81 and oncogenic HER2/Neu,Ras,or Raf显示文摘 | Goueli BS Janknecht R | 2004 | Mol Cell Biol2004，24，1： | 1 |
| 7 | Selective in vivo inhibition of mitogen-activated protein kinase activation using cell-permeable peptides显示文摘 | Kelemen BR Hsiao K Goueli SA | 2002 | J Biol Chem2002，277，10： | 1 |
| 8 | Sustained Activation of the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway is required for megakaryocytic differentiation ofK562 cells显示文摘 | Racke FK Lewandowska K Goueli S | 1997 | J Biol Chem1997，272，23： | 1 |
| 9 | Sustained activation of the extracellular signal-regulated kinase mitogen-activated protein kinase pathway is required for megakaryocytic differentiation of K562 cells 显示文摘 | Racke FK Lewandowska K Goueli S | 1997 | J Biol Chem1997，272，23： | 1 |
| 10 | Upregulation of the catalytic telomerase subunit by the transcription factor ER81 and oncogenic HER2/Neu,Ras,or Raf显示文摘 | Goueli BS Janknecht R | 2004 | Mol Cell Biol2004，24，1： | 1 |
| 11 | Selective in vivo inhibition of mitogen-activated protein kinase activation using cell-permeable peptides显示文摘 | Kelemen BR Hsiao K Goueli SA | 2002 | J Biol Chem2002，277，10： | 1 |
| 12 | Upregulation of the Catalytic Telomerase Subunit by the Transcription Factor ER81 and Oncogenic HER2/ Neu, Ras, or Raf 显示文摘 | GOUELI BS JANKNECHT R | 2004 | Mol Cell Biol2004，24，： | 1 |
| 13 | Upregulation of the catalytic telomerase subunit by the transcription factor ER81 and oncogenic HER2 / Neu, Ras, or Raf显示文摘 | Goueli BS Janknecht R | 2004 | Mol Cell Biol2004，24，1： | 1 |
| 14 | Sustained Activation of the extracellular signal-regulated kinase/Mitogen-activated protein kinase pathway is required for megakaryocytic differentiation of K562 cells显示文摘 | Racke F K Lewandowska K Goueli S | 1997 | J Bial Chen1997，272，23： | 1 |
| 15 | Up regulation of the catalytic telomerase subunit by the transcription factor ER81and oncogenic HER2/Neu, Ras, or Raf显示文摘 | Goueli BS Janknccht R | 2004 | Mol Cell Biol2004，24，： | 1 |
| 16 | Upregulation of the Catalytic Telomerase Subunit by the Transcription Factor ER81 and Oncogenic HER2/Neu, Ras, or Raf 显示文摘 | Goueli B S Janknecht R | 2004 | Mol Cell Bid2004，24，1： | 1 |
| 17 | Selective in Vivo Inhibition of Mitogen-activated Protein Kinase Activation Using Cell-permeable Peptides显示文摘 | Kelemen BR Hsiao K Goueli SA | 2002 | Biol Chem2002，277，10： | 1 |
| 18 | Positional effect of mutations in 5'UTR of hepatitis C virus 4a on patients' response to therapy显示文摘AIM:To investigate the effects of mutations in domain Ⅲ of the hepatitis C virus(HCV)internal ribosome entry sequences(IRES)on the response of chronic HCV genotype 4a patients to interferon therapy.METHODS:HCV RNA was extracted from 19 chronic HCV 4a patients receiving interferon/ribavirin therapy who showed dramatic differences in their response to combination therapy after initial viral clearance.IRES domainⅢ was cloned and 15 clones for each patient were sequenced.The obtained sequences were aligned with genotype 4a prototype using the ClustalW program and mutations scored.Prediction of stem-loop secondary structure and thermodynamic stability of the major quasispecies in each patient was performed using the MFOLD 3.2 program with Turner energies and selected constraints on base pairing.RESULTS:Analysis of RNA secondary structure revealed that insertions in domainⅢ altered WatsonCrick base pairing of stems and reduced molecular stability of RNA,which may ultimately reduce binding affinity to ribosomal proteins.Insertion mutations in domainⅢwere statistically more prevalent in sustained viral response patients(SVR,n=14)as compared to breakthrough(BT,n=5)patients.CONCLUSION:The influence of mutations within domainⅢ on the response of HCV patients to combination therapy depends primarily on the position,but not the frequency,of these mutations within IRES domain Ⅲ. | Mostafa K El Awady Hassan M Azzazy Ahmed M Fahmy Sherif M Shawky Noha G Badreldin Samar S Yossef Moataza H Omran Abdel Rahman N Zekri Said A Goueli | 2009 | World Journal of Gastroenterology2009，15，12： | 1 |
| 19 | Upregulation of the catalytic telomerasesubunit by the transcription factor ER81 and oncogenic HER2/Neu,Ras or Raf显示文摘 | Goueli BS Janknecht R | 2004 | Mol Cell Biol2004，24，1： | 1 |
| 20 | Upregulation of the catalytic telomerase subunit by the transcription factor ER81 and oncogenic HER2/Neu,Ras,or Raf显示文摘 | Goueli BS Janknecht R | 2004 | Mol Cell Biol2004，24，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员